Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure (BENEFICIAL)
A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
Sponsor: Synvista Therapeutics, Inc
Terminated
Study has been termination early due to financial constraints.
Other terminated trials from Synvista Therapeutics, Inc
- Diastolic Heart Failure · Phase PHASE2 · Dec 2009
- Psoriasis · Phase PHASE2 · Mar 2009
- Hypertension · Phase PHASE2
More terminations from Synvista Therapeutics, Inc
Other Chronic Heart Failure trials with similar outcome
A PHASE2 clinical study on Chronic Heart Failure, this trial is terminated or withdrawn. The trial is conducted by Synvista Therapeutics, Inc and has accumulated 6 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Synvista Therapeutics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .